PolyU is exploring collaboration on biomedicine research projects in Shanghai and Hong Kong with Shanghai Pharmaceutical (SPH) and its subsidiary Biopharma Evolution, aiming to pool the three institutions’ expertise to contribute to the Nation’s biomedical research and development.

Under a newly signed Memorandum of Understanding (MoU) between the three parties this month, regular academic exchange activities will be organised to proactively identify potential research projects and other cooperative opportunities.

PolyU has been exploring collaboration with SPH on the development of new drugs in the areas of targeted therapies, protein interaction inhibitors and autophagy modulators.

The cooperation between PolyU, SPH and Biopharma Evolution will accelerate translational projects and eventually lead to the development of new drugs to benefit mankind.

The MoU was signed online by Prof. Wang Zuankai, Associate Vice President (Research and Innovation) of PolyU and Mr Zuo Min, President of Shanghai Pharmaceuticals Holding Co., Ltd. and Biopharma Evolution during the 2022 Pujiang Healthcare Industry & Finance Integration and Innovation Summit held in Shanghai this month.